Biocon Biologics received five FDA observations, will submit a CAPA plan, ensure no product supply impact, and remain compliant.

• FDA inspection covered manufacturing, QC labs, microbiology labs, and warehouses over nine days, concluding with five procedural observations issued.
• Biocon confirmed no concerns regarding data integrity, systemic non-compliance, or quality oversight in the issued FDA observations.
• The company is committed to corrective actions, timely CAPA submission, and ensuring an uninterrupted supply of affordable therapies for chronic health conditions.